This is also Sun Pharma's second acquisition in less than three months and comes as the company looks to size up its specialty therapy portfolio.

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

COLUMBUS (WRBL) – The Columbus State Women’s Basketball team is back in the NCAA Division II Tournament, earning the number 5 seed in the Southeast Regional. The Lady Cougars will take on ...

COLUMBUS, Ga (WRBL) — Columbus State will be well represented in the field of 64, making up the NCAA Division II tournament. Both the men and womens teams will be participating.

Checkpoint has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or ...

and cutaneous squamous cell carcinoma (CSCC), as well as combination expansion arms in metastatic melanoma, RCC, and non-small cell lung cancer (NSCLC). Of the five previously disclosed objective ...

COLUMBUS, Ga. (WTVM) - The Columbus Lions are eager for league action after their impressive home opener victory against Peach State. The Lions defeated the Cats 85 to 0 on March 9 in their first ...

Hohem, a global leader in gimbal technology, is delighted to announce its participation in the Photography & Video Show 2025, ...

and cutaneous squamous cell carcinoma (CSCC), as well as combination expansion arms in metastatic melanoma, RCC, and non-small cell lung cancer (NSCLC). Of the five previously disclosed objective ...

for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC, who are not candidates for curative surgery or curative radiation. Dilip Shanghvi ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half ...